Los puntos clave no están disponibles para este artículo en este momento.
In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.
O’Brien et al. (Thu,) studied this question.